Dr Nicole Clarke
Profiles

Dr Nicole Clarke

Lecturer in Biomedical Sciences

Peninsula Medical School (Faculty of Health)

Biography

Biography

Nicole Clarke gained a PhD from the Department of Biological Sciences at Columbia University in New York. She then carried out a postdoctoral fellowship in Strasbourg, France at the IGBMC studying the anti-cancer activity of retinoids and HDAC inhibitors. Nicole then took up a Lectureship at the University of Nottingham in the School of Pharmacy. where she taught on the MPharm programme and carried out research on the tumour suppressor activity of the transcription factor IRF1. Her research has been published in the journals, Nature Medicine, Nucleic Acids Research, EMBO journal, and Cell Death and Differentiation. She has recently joined the Peninsula Medical School as a Lecturer in Biomedical Sciences. Nicole's research interests are in the area of cancer research with specific interests in tumour suppressor regulation and activity.

Qualifications

BSc, University of Toronto

MSc, MPhil, Columbia University

PhD, Columbia University

AFHEA, University of Nottingham

Teaching

Teaching

Teaching interests

Teaching:

MED003  Learning Skills and Professional Development for Medicine

FMD004  Interdisciplinary Learning and Team Based Learning (Enquiry learning)

EBL      Enquiry Based Learning

Publications

Publications

Key publications

Key publications are highlighted

Journals
Articles
Garvin AJ, Khalaf AHA, Rettino A, Xicluna J, Butler L, Morris JR, Heery DM & Clarke NM (2019) 'GSK3β-SCFFBXW7α mediated phosphorylation and ubiquitination of IRF1 are required for its transcription-dependent turnover' Nucleic Acids Research 47, (9) 4476-4494 , DOI
Frontini M, Vijayakumar M, Garvin A & Clarke N (2009) 'A ChIP–chip approach reveals a novel role for transcription factor IRF1 in the DNA damage response' Nucleic Acids Research 37, (4) 1073-1085 , DOI
Benosman S, Gross I, Clarke N, Jochemsen AG, Okamoto K, Loeffler J-P & Gaiddon C (2007) 'Multiple neurotoxic stresses converge on MDMX proteolysis to cause neuronal apoptosis' Cell Death & Differentiation 14, (12) 2047-2057 , DOI
Altucci L, Clarke N, Nebbioso A, Scognamiglio A & Gronemeyer H (2005) 'Acute myeloid leukemia: Therapeutic impact of epigenetic drugs' The International Journal of Biochemistry & Cell Biology 37, (9) 1752-1762 , DOI
Clarke N, Nebbioso A, Altucci L & Gronemeyer H (2005) 'TRAIL: At the Center of Drugable Anti-Tumor Pathways' Cell Cycle 4, (7) 914-918 , DOI
Nebbioso A, Clarke N, Voltz E, Germain E, Ambrosino C, Bontempo P, Alvarez R, Schiavone EM, Ferrara F & Bresciani F (2004) 'Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells' Nature Medicine 11, (1) 77-84 , DOI
Clarke N, Germain P, Altucci L & Gronemeyer H (2004) 'Retinoids: potential in cancer prevention and therapy' Expert Reviews in Molecular Medicine 6, (25) 1-23 , DOI
Jiménez-Lara AM, Clarke N, Altucci L & Gronemeyer H (2004) 'Retinoic-acid-induced apoptosis in leukemia cells' Trends in Molecular Medicine 10, (10) 508-515 , DOI
Clarke N, Jimenez-Lara AM, Voltz E & Gronemeyer H (2004) 'Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL' The EMBO Journal 23, (15) 3051-3060 , DOI
Clarke N, Arenzana N, Hai T, Minden A & Prywes R (1998) 'Epidermal Growth Factor Induction of the c- jun Promoter by a Rac Pathway' Molecular and Cellular Biology 18, (2) 1065-1073 , DOI